Using the tau assay, recent reports are consistently showing major interindividual variability of seeding potency of AD brain-derived tau [160,165,166] and homogenates of rapidly progressing AD cases demonstrate a significantly shorter lag phase than classical slowly progressing cases [10]. The gene discussed is MAPT; the disease is Alzheimer disease.